Factor VII-verteporfin for targeted photodynamic therapy in a rat model of choroidal neovascularization

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 8, 2009, Pages 3890-3896

  Lu, Fang ^a,b   Hu, Zhiwei ^a   Sinard, John ^a   Garen, Alan ^a   Adelman, Ron A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 7; THROMBOPLASTIN; VERTEPORFIN; PHOTOSENSITIZING AGENT; PORPHYRIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BROWN NORWAY RAT; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; ENDOTHELIUM CELL; EXPERIMENTAL MODEL; FEMALE; FLUORESCENCE ANGIOGRAPHY; HISTOPATHOLOGY; LASER COAGULATION; MOUSE; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RETINA; SUBRETINAL NEOVASCULARIZATION; ANIMAL; CAPILLARY PERMEABILITY; DISEASE MODEL; DRUG DELIVERY SYSTEM; DRUG EFFECT; INTRAVENOUS DRUG ADMINISTRATION; PATHOLOGY; PHOTOCHEMOTHERAPY; RETINA BLOOD VESSEL;

ANIMALS; CAPILLARY PERMEABILITY; CHOROIDAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; FACTOR VII; FLUORESCEIN ANGIOGRAPHY; INJECTIONS, INTRAVENOUS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; RATS; RATS, INBRED BN; RETINAL VESSELS;

EID: 68349108002     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-2833     Document Type: Article

References (16)

1. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report 1. Arch Ophthalmol. 1999;117:1329-1345.
2. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials. TAP report 2. Arch Ophthalmol. 2001;119:198-207.
3. Husain D, Kramer M, Kenny AG, et al. Effects of photodynamic therapy using verteporfin on experimental choroidal neovascularization and normal retina and choroid up to 7 weeks after treatment. Invest Ophthalmol Vis Sci. 1999;40:2322-2331.
4. Miller JW, Schmidt-Erfurth U, Sickenberg M, et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol. 1999;117:1161-1173.
5. Brown SB, Mellish KJ. Verteporfin: a milestone in ophthalmology and photodynamic therapy. Expert Opin Pharmacother. 2001;2: 351-361.
6. Hu Z, Sun Y, Garen A. Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model. Proc Natl Acad Sci U S A. 1999;96:8161-8166.
7. Hu Z, Garen A. Intratumoral injection of adenoviral vectors encoding tumor-targeted immunoconjugates for cancer immunotherapy. Proc Natl Acad Sci U S A. 2000;97:9221-9225.
8. Hu Z, Garen A. Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer. Proc Natl Acad Sci U S A. 2001;98:12180-12185.
9. Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med. 1996;2: 209-215.
10. Tang Y, Borgstrom P, Maynard J, et al. Mapping of angiogenic markers for targeting of vectors to tumor vascular endothelial cells. Cancer Gene Ther. 2007;14:346-353.
11. Bora PS, Hu Z, Tezel TH, et al. Immunotherapy for choroidal neovascularization in a laser-induced mouse model simulating exudative (wet) macular degeneration. Proc Natl Acad Sci U S A. 2003;100:2679-2684.
12. Tezel TH, Bodek E, Sonmez K, et al. Targeting tissue factor for immunotherapy of choroidal neovascularization by intravitreal delivery of factor VII-Fc chimeric antibody. Ocular Immunol Inflamm. 2007;15:3-10.
13. Zacks DN, Ezra E, Terada Y, et al. Verteporfin photodynamic therapy in the rat model of choroidal neovascularization: angiographic and histologic characterization. Invest Ophthalmol Vis Sci. 2002;43:2384-2391.
14. Kim JS, Raines RT. Ribonuclease S-peptide as a carrier in fusion proteins. Protein Sci. 1993;2:348-356.
15. Renno RZ, Terada Y, Haddadin MJ, Michaud NA, Gragoudas ES, Miller JW. Selective photodynamic therapy by targeted verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor-2. Arch Ophthalmol. 2004;122:1002-1011.
16. Gilpin DA. Calculation of a new Meeh constant and experimental determination of burn size. Burns. 1996;22:607-611.